Determination of plasma imipenem in critically ill patients by HPLC and research on PK/PD targeted attainment

Ling GUO,Xue-mei LUO,Pei LIANG,Wei-hong GE

DOI: https://doi.org/10.13286/j.cnki.chinhosppharmacyj.2017.16.12

2017-01-01

Abstract:OBJECTIVE To establish an HPLC method for the determination of imipenem in plasma of critically ill patients to compare the results of patients who received continuous renal replacement therapy (CRRT) with those who did not receive the therapy,and to provide evidences for drug adjustment.METHODS With 0.5 mol·L-1 3-morpholine-propane sulfonic acid buffer (pH 6-8)-ethylene-glycol-water (2∶1∶1) as the stabilizer,with 5-hydroxy-indole-3 acetic acid as the internal standard,samples were deproteinized by centrifugation using ultrafiltration pretreatment tube.Separation was performed on a TSKgel ODS-100V column (4.6 mm× 250 mm,5 μm).The mobile phase was composed of methanol and 10 mmol·L-1KH2PO4 (pH 6.7-7.0,6∶94) with a flow rate of 0.9 mL·min-1.The detection wavelength was 300 nm,the column temperature was 30 ℃,and the injection volume was 30 μL.The method was applied in the determination of trough plasma imipenem concentrations from 33 critically ill patients who took imipenem/cilastatin.There were 14 patients in CRRT group and 19 in non-CRRT group.The dosage regimens were evaluated with 100％T＞ MIC as the PK/PD target.RESULTS Calibration curves of imi penem showed a good linearity in the range of 0.5-50 μg · mL-1.The lower limit of quantification of imipenem was 0.5 μg· mL-1.Intra-and inter-day variations were all ＜10％.The stability test showed that imipenem was stable during sample processing.At MIC＞2μg·mL-1,the number of patients who met the criterion significantly reduced.CRRT-treated patients achieved a lower ％T＞MIC than those who did not receive the therapy.CONCLUSION The method is simple,sensitive,accurate and fast,and is applicable to the guidance for individualized imipenem use in clinical practice.